Summary:
A Phase 1, Open-label, Multicohort Study to Evaluate the Impact of Inhibitors and Inducers of Cytochrome P450 Enzyme (CYP)3A and/or P-glycoprotein (P-gp) on the Pharmacokinetics (PK) of Vesatolimod (VES) in Virologically Suppressed Adults With HIV-1 on Antiretroviral Therapy (ART).
Qualified Participants Must:
• Be atleast 18 years old
• Be diagnosed with HIV-1
• Be currently on an ART regimen for at least 6 consecutive months, with no change in the ART regimen within 2 months prior to screening
• Refrain from the use of nicotine or nicotine-containing products 90 days prior to first dose of study drug and during the course of the study through the follow-up visit
Qualified Participants May Receive:
- Up to $4,000
- Tranportation available and no insurance needed